Marshall Wace’s Vir Biotechnology VIR Stock Holding History

Marshall Wace’s Portfolio VIR Stock Details VIR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-23,557	Closed	-$173K	–	3126
2024 Q4	$173K	Buy	+23,557	New	+$186K	﹤0.01%	2379
2023 Q3	–	Sell	-73,641	Closed	-$1.81M	–	2729
2023 Q2	$1.81M	Sell	73,641 -9,920	-12%	-$249K	﹤0.01%	1451
2023 Q1	$1.94M	Sell	83,561 -114,429	-58%	-$2.93M	﹤0.01%	1470
2022 Q4	$5.01M	Sell	197,990 -148,286	-43%	-$3.63M	0.01%	1184
2022 Q3	$6.68M	Buy	346,276 +90,200	+35%	+$2.29M	0.01%	1169
2022 Q2	$6.52M	Buy	+256,076	New	+$5.98M	0.01%	1158
2022 Q1	–	Sell	-352,171	Closed	-$14.7M	–	4063
2021 Q4	$14.7M	Buy	352,171 +293,552	+501%	+$11.5M	0.03%	624
2021 Q3	$2.55M	Buy	+58,619	New	+$2.54M	0.01%	1376
2021 Q2	–	Sell	-39,560	Closed	-$2.03M	–	3124
2021 Q1	$2.03M	Buy	+39,560	New	+$2.13M	0.01%	1318

Other funds holding VIR

SIAU

SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Marshall Wace's VIR Position: Q1 2025 in Review

Marshall Wace sold out of Vir Biotechnology (VIR) in Q1 2025, closing a stake of 23,557 shares — an estimated $173K sold.

Marshall Wace first reported a position in VIR in Q1 2021 and held it in 9 quarters. The position peaked at $14.7M in Q4 2021. 233 funds tracked by Wall St. Rank hold VIR as of Q1 2025.

Marshall Wace reported no remaining Vir Biotechnology position as of Q1 2025 after selling out during the quarter.
Marshall Wace sold 23,557 Vir Biotechnology shares in Q1 2025, an estimated $173K.
Marshall Wace first reported a position in Vir Biotechnology in Q1 2021 and held it in 9 quarters.
Marshall Wace's Vir Biotechnology position peaked at $14.7M in Q4 2021.
233 funds tracked by Wall St. Rank held Vir Biotechnology as of Q1 2025.

Based on Marshall Wace's 13F filing for Q1 2025, filed 15 May 2025.